{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:02:10Z","timestamp":1750737730654,"version":"3.41.0"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Die chronische Rhinosinusitis stellt eine der h\u00e4ufigsten chronischen Erkrankungen des oberen Atemwegs dar und geht mit einer deutlichen Einschr\u00e4nkung der Lebensqualit\u00e4t einher. Eine pr\u00e4zise Diagnostik ist notwendig, um Patienten einer suffizienten Therapie zuf\u00fchren zu k\u00f6nnen. Durch die Einf\u00fchrung von Biologika haben sich neue Optionen zur Behandlung schwer betroffener Patienten mit chronischer Rhinosinusitis mit Nasenpolypen im Sinne der Pr\u00e4zisionsmedizin ergeben, die \u00fcber die alleinige Kontrolle der Symptome hinausgehen. Damit einher ging eine gewisse Standardisierung in Bezug auf diagnostische Verfahren und die Erfassung der krankheitsspezifischen Lebensqualit\u00e4t. Im Rahmen des vorliegenden Referats soll vor dem Hintergrund des Kongressthemas 2025 \u201eIndividualisierung vs. Standardisierung in der HNO-Heilkunde\u201c die Diagnostik und medikament\u00f6se Therapie der chronischen Rhinosinusitis mit Schwerpunkt auf die Biologikatherapie beleuchtet und zusammengefasst werden.<\/jats:p>","DOI":"10.1007\/s00106-025-01635-y","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T13:39:01Z","timestamp":1744810741000},"page":"441-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostik und medikament\u00f6se Therapie der chronischen Rhinosinusitis","Diagnosis and drug therapy of chronic rhinosinusitis"],"prefix":"10.1007","volume":"73","author":[{"given":"Sven","family":"Becker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"1635_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JAA.S290424","volume":"14","author":"C Bachert","year":"2021","unstructured":"Bachert\u00a0C, Bhattacharyya\u00a0N, Desrosiers\u00a0M, Khan\u00a0AH (2021) Burden of disease in chronic Rhinosinusitis with nasal polyps. J\u00a0Asthma Allergy 14:127\u2013134. https:\/\/doi.org\/10.2147\/JAA.S290424","journal-title":"J Asthma Allergy"},{"key":"1635_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2500\/ajra.2013.27.3981","volume":"27","author":"MR Chaaban","year":"2013","unstructured":"Chaaban\u00a0MR, Walsh\u00a0EM, Woodworth\u00a0BA (2013) Epidemiology and differential diagnosis of nasal polyps. am j rhinol allergy 27:473\u2013478. https:\/\/doi.org\/10.2500\/ajra.2013.27.3981","journal-title":"am j rhinol allergy"},{"key":"1635_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4193\/Rhin20.601","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens\u00a0WJ et\u00a0al (2020) Executive summary of EPOS 2020 including integrated care pathways. Rhinology 58:82\u2013111. https:\/\/doi.org\/10.4193\/Rhin20.601","journal-title":"Rhinology"},{"key":"1635_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens\u00a0WJ et\u00a0al (2020) European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology 58:1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","journal-title":"Rhinology"},{"key":"1635_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00106-023-01273-2","volume":"71","author":"O Pfaar","year":"2023","unstructured":"Pfaar\u00a0O, Beule\u00a0AG, Laudien\u00a0M, Stuck\u00a0BA (2023) Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with monoclonal antibodies (biologics): S2k guideline of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), and the German College of General Practitioners and Family Physicians (DEGAM). HNO 71:256\u2013263. https:\/\/doi.org\/10.1007\/s00106-023-01273-2 (erweiterte Leitliniengruppe Biologika bei, C)","journal-title":"HNO"},{"issue":"Suppl 1","key":"1635_CR6","first-page":"1","volume":"21","author":"I Alobid","year":"2011","unstructured":"Alobid\u00a0I et\u00a0al (2011) SEAIC-SEORL. Consensus Document on Nasal Polyposis. POLINA Project. J\u00a0Investig Allergol Clin Immunol 21(Suppl 1):1\u201358","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1635_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","volume":"66","author":"D Hastan","year":"2011","unstructured":"Hastan\u00a0D et\u00a0al (2011) Chronic rhinosinusitis in Europe\u2014an underestimated disease. A\u00a0GA(2)LEN study. Allergy 66:1216\u20131223. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02646.x","journal-title":"Allergy"},{"key":"1635_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1398-9995.2011.02709.x","volume":"67","author":"D Jarvis","year":"2012","unstructured":"Jarvis\u00a0D et\u00a0al (2012) Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy 67:91\u201398. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02709.x","journal-title":"Allergy"},{"key":"1635_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11882-017-0690-5","volume":"17","author":"L Rudmik","year":"2017","unstructured":"Rudmik\u00a0L (2017) Economics of chronic Rhinosinusitis. Curr Allergy Asthma Rep 17:20. https:\/\/doi.org\/10.1007\/s11882-017-0690-5","journal-title":"Curr Allergy Asthma Rep"},{"key":"1635_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00043764-200301000-00007","volume":"45","author":"RZ Goetzel","year":"2003","unstructured":"Goetzel\u00a0RZ, Hawkins\u00a0K, Ozminkowski\u00a0RJ, Wang\u00a0S (2003) The health and productivity cost burden of the \u201etop 10\u201c physical and mental health conditions affecting six large U.S. employers in 1999. J\u00a0Occup Environ Med 45:5\u201314. https:\/\/doi.org\/10.1097\/00043764-200301000-00007","journal-title":"J Occup Environ Med"},{"key":"1635_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/0194599815572097","volume":"152","author":"RM Rosenfeld","year":"2015","unstructured":"Rosenfeld\u00a0RM et\u00a0al (2015) Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 152:S1\u2013S39. https:\/\/doi.org\/10.1177\/0194599815572097","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1635_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00106-017-0401-5","volume":"66","author":"BA Stuck","year":"2018","unstructured":"Stuck\u00a0BA et\u00a0al (2018) Guideline for \u201erhinosinusitis\u201c-long version : S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery. HNO 66:38\u201374. https:\/\/doi.org\/10.1007\/s00106-017-0401-5","journal-title":"HNO"},{"key":"1635_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/all.16417","volume":"80","author":"WJ Fokkens","year":"2025","unstructured":"Fokkens\u00a0WJ et\u00a0al (2025) Algorithm for the management of primary diffuse chronic Rhinosinusitis. Allergy 80:359\u2013361. https:\/\/doi.org\/10.1111\/all.16417","journal-title":"Allergy"},{"key":"1635_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/lary.25052","volume":"125","author":"BR Haxel","year":"2015","unstructured":"Haxel\u00a0BR et\u00a0al (2015) Controlled trial for long-term low-dose erythromycin after sinus surgery for chronic rhinosinusitis. Laryngoscope 125:1048\u20131055. https:\/\/doi.org\/10.1002\/lary.25052","journal-title":"Laryngoscope"},{"key":"1635_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011994.pub2","author":"K Head","year":"2016","unstructured":"Head\u00a0K et\u00a0al (2016) Systemic and topical antibiotics for chronic rhinosinusitis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011994.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1635_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.anl.2011.04.015","volume":"39","author":"Y Majima","year":"2012","unstructured":"Majima\u00a0Y et\u00a0al (2012) Efficacy of combined treatment with S\u2011carboxymethylcysteine (carbocisteine) and clarithromycin in chronic rhinosinusitis patients without nasal polyp or with small nasal polyp. Auris Nasus Larynx 39:38\u201347. https:\/\/doi.org\/10.1016\/j.anl.2011.04.015","journal-title":"Auris Nasus Larynx"},{"key":"1635_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/01.mlg.0000191560.53555.08","volume":"116","author":"B Wallwork","year":"2006","unstructured":"Wallwork\u00a0B, Coman\u00a0W, Mackay-Sim\u00a0A, Greiff\u00a0L, Cervin\u00a0A (2006) A\u00a0double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope 116:189\u2013193. https:\/\/doi.org\/10.1097\/01.mlg.0000191560.53555.08","journal-title":"Laryngoscope"},{"key":"1635_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins\u00a0FS, Varmus\u00a0H (2015) A\u00a0new initiative on precision medicine. N\u00a0Engl J Med 372:793\u2013795. https:\/\/doi.org\/10.1056\/NEJMp1500523","journal-title":"N Engl J Med"},{"key":"1635_CR19","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/all.13162","volume":"72","author":"PW Hellings","year":"2017","unstructured":"Hellings\u00a0PW et\u00a0al (2017) Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis\u2014A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy 72:1297\u20131305. https:\/\/doi.org\/10.1111\/all.13162","journal-title":"Allergy"},{"key":"1635_CR20","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1111\/all.15054","volume":"76","author":"I Agache","year":"2021","unstructured":"Agache\u00a0I et\u00a0al (2021) Advances and highlights in asthma in 2021. Allergy 76:3390\u20133407. https:\/\/doi.org\/10.1111\/all.15054","journal-title":"Allergy"},{"key":"1635_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.jaci.2013.02.036","volume":"131","author":"CA Akdis","year":"2013","unstructured":"Akdis\u00a0CA et\u00a0al (2013) Endotypes and phenotypes of chronic rhinosinusitis: a\u00a0PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J\u00a0Allergy Clin Immunol 131:1479\u20131490. https:\/\/doi.org\/10.1016\/j.jaci.2013.02.036","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR22","doi-asserted-by":"publisher","first-page":"579409","DOI":"10.3389\/fimmu.2020.579409","volume":"11","author":"S Blank","year":"2020","unstructured":"Blank\u00a0S, Grosch\u00a0J, Ollert\u00a0M, Bilo\u00a0MB (2020) Precision medicine in hymenoptera venom allergy: diagnostics, biomarkers, and therapy of different endotypes and phenotypes. Front Immunol 11:579409. https:\/\/doi.org\/10.3389\/fimmu.2020.579409","journal-title":"Front Immunol"},{"key":"1635_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaci.2022.07.021","volume":"151","author":"JW Hui-Beckman","year":"2023","unstructured":"Hui-Beckman\u00a0JW, Goleva\u00a0E, Berdyshev\u00a0E, Leung\u00a0DYM (2023) Endotypes of atopic dermatitis and food allergy. J\u00a0Allergy Clin Immunol 151:26\u201328. https:\/\/doi.org\/10.1016\/j.jaci.2022.07.021","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/all.13132","volume":"72","author":"A Muraro","year":"2017","unstructured":"Muraro\u00a0A et\u00a0al (2017) Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 72:1006\u20131021. https:\/\/doi.org\/10.1111\/all.13132","journal-title":"Allergy"},{"key":"1635_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/all.12573","volume":"70","author":"NG Papadopoulos","year":"2015","unstructured":"Papadopoulos\u00a0NG et\u00a0al (2015) Phenotypes and endotypes of rhinitis and their impact on management: a\u00a0PRACTALL report. Allergy 70:474\u2013494. https:\/\/doi.org\/10.1111\/all.12573","journal-title":"Allergy"},{"key":"1635_CR26","doi-asserted-by":"publisher","first-page":"e0200366","DOI":"10.1371\/journal.pone.0200366","volume":"13","author":"CL Segboer","year":"2018","unstructured":"Segboer\u00a0CL, Fokkens\u00a0WJ, Terreehorst\u00a0I, van Drunen\u00a0CM (2018) Endotyping of non-allergic, allergic and mixed rhinitis patients using a\u00a0broad panel of biomarkers in nasal secretions. PLoS ONE 13:e200366. https:\/\/doi.org\/10.1371\/journal.pone.0200366","journal-title":"PLoS ONE"},{"key":"1635_CR27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","volume":"140","author":"JL Thijs","year":"2017","unstructured":"Thijs\u00a0JL et\u00a0al (2017) Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis. J\u00a0Allergy Clin Immunol 140:730\u2013737. https:\/\/doi.org\/10.1016\/j.jaci.2017.03.023","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR28","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1111\/all.15889","volume":"78","author":"M Jutel","year":"2023","unstructured":"Jutel\u00a0M et\u00a0al (2023) Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper. Allergy 78:2851\u20132874. https:\/\/doi.org\/10.1111\/all.15889","journal-title":"Allergy"},{"key":"1635_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2019.05.009","volume":"46","author":"I Eguiluz-Gracia","year":"2019","unstructured":"Eguiluz-Gracia\u00a0I, Layhadi\u00a0JA, Rondon\u00a0C, Shamji\u00a0MH (2019) Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol 46:100\u2013107. https:\/\/doi.org\/10.1016\/j.coph.2019.05.009","journal-title":"Curr Opin Pharmacol"},{"key":"1635_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy\u00a0JV (2015) Type\u00a02 inflammation in asthma\u2014present in most, absent in many. Nat Rev Immunol 15:57\u201365. https:\/\/doi.org\/10.1038\/nri3786","journal-title":"Nat Rev Immunol"},{"key":"1635_CR31","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1111\/all.15751","volume":"78","author":"L Gigon","year":"2023","unstructured":"Gigon\u00a0L, Fettrelet\u00a0T, Yousefi\u00a0S, Simon\u00a0D, Simon\u00a0HU (2023) Eosinophils from A to Z. Allergy 78:1810\u20131846. https:\/\/doi.org\/10.1111\/all.15751","journal-title":"Allergy"},{"key":"1635_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaci.2017.02.038","volume":"141","author":"K Sugita","year":"2018","unstructured":"Sugita\u00a0K et\u00a0al (2018) Type\u00a02 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J\u00a0Allergy Clin Immunol 141:300\u2013310.e11. https:\/\/doi.org\/10.1016\/j.jaci.2017.02.038","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jaci.2016.03.050","volume":"139","author":"P Wawrzyniak","year":"2017","unstructured":"Wawrzyniak\u00a0P et\u00a0al (2017) Regulation of bronchial epithelial barrier integrity by type\u00a02 cytokines and histone deacetylases in asthmatic patients. J\u00a0Allergy Clin Immunol 139:93\u2013103. https:\/\/doi.org\/10.1016\/j.jaci.2016.03.050","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fimmu.2020.00127","volume":"11","author":"TA McLaughlin","year":"2020","unstructured":"McLaughlin\u00a0TA et\u00a0al (2020) CD4 T Cells in Mycobacterium tuberculosis and Schistosoma mansoni Co-infected Individuals Maintain Functional TH1 Responses. Front Immunol 11:127. https:\/\/doi.org\/10.3389\/fimmu.2020.00127","journal-title":"Front Immunol"},{"key":"1635_CR35","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.cell.2018.10.001","volume":"175","author":"MO Johnson","year":"2018","unstructured":"Johnson\u00a0MO et\u00a0al (2018) Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell 175:1780\u20131795.e19. https:\/\/doi.org\/10.1016\/j.cell.2018.10.001","journal-title":"Cell"},{"key":"1635_CR36","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-021-00538-7","volume":"21","author":"CA Akdis","year":"2021","unstructured":"Akdis\u00a0CA (2021) Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol 21:739\u2013751. https:\/\/doi.org\/10.1038\/s41577-021-00538-7","journal-title":"Nat Rev Immunol"},{"key":"1635_CR37","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/all.15240","volume":"77","author":"Z Celebi Sozener","year":"2022","unstructured":"Celebi Sozener\u00a0Z et\u00a0al (2022) Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease. Allergy 77:1418\u20131449. https:\/\/doi.org\/10.1111\/all.15240","journal-title":"Allergy"},{"key":"1635_CR38","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1111\/all.15762","volume":"78","author":"K Saito","year":"2023","unstructured":"Saito\u00a0K et\u00a0al (2023) Laundry detergents and surfactants-induced eosinophilic airway inflammation by increasing IL-33 expression and activating ILC2s. Allergy 78:1878\u20131892. https:\/\/doi.org\/10.1111\/all.15762","journal-title":"Allergy"},{"key":"1635_CR39","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.immuni.2016.10.031","volume":"45","author":"IM de Kleer","year":"2016","unstructured":"de Kleer\u00a0IM et\u00a0al (2016) Perinatal activation of the Interleukin-33 pathway promotes type\u00a02 immunity in the developing lung. Immunity 45:1285\u20131298. https:\/\/doi.org\/10.1016\/j.immuni.2016.10.031","journal-title":"Immunity"},{"key":"1635_CR40","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jaci.2012.05.052","volume":"130","author":"MB Soyka","year":"2012","unstructured":"Soyka\u00a0MB et\u00a0al (2012) Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL\u20114. J\u00a0Allergy Clin Immunol 130:1087\u20131096.e10. https:\/\/doi.org\/10.1016\/j.jaci.2012.05.052","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR41","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/JAA.S413064","volume":"16","author":"TM Laidlaw","year":"2023","unstructured":"Laidlaw\u00a0TM et\u00a0al (2023) Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J\u00a0Asthma Allergy 16:915\u2013932. https:\/\/doi.org\/10.2147\/JAA.S413064","journal-title":"J Asthma Allergy"},{"key":"1635_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/all.13599","volume":"74","author":"ML Kowalski","year":"2019","unstructured":"Kowalski\u00a0ML et\u00a0al (2019) Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)\u2014a EAACI position paper. Allergy 74:28\u201339. https:\/\/doi.org\/10.1111\/all.13599","journal-title":"Allergy"},{"key":"1635_CR43","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1056\/NEJMra1712125","volume":"379","author":"AA White","year":"2018","unstructured":"White\u00a0AA, Stevenson\u00a0DD (2018) Aspirin-exacerbated respiratory disease. N\u00a0Engl J Med 379:1060\u20131070. https:\/\/doi.org\/10.1056\/NEJMra1712125","journal-title":"N Engl J Med"},{"key":"1635_CR44","doi-asserted-by":"publisher","first-page":"734733","DOI":"10.3389\/falgy.2021.734733","volume":"2","author":"A Lyly","year":"2021","unstructured":"Lyly\u00a0A, Laidlaw\u00a0TM, Lundberg\u00a0M (2021) Pathomechanisms of AERD-recent advances. Front Allergy 2:734733. https:\/\/doi.org\/10.3389\/falgy.2021.734733","journal-title":"Front Allergy"},{"key":"1635_CR45","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","volume":"9","author":"N Bavaro","year":"2021","unstructured":"Bavaro\u00a0N et\u00a0al (2021) Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL\u20115 or anti-IL-5Ralpha in a\u00a0real-world setting. J\u00a0Allergy Clin Immunol Pract 9:2910\u20132912.e11. https:\/\/doi.org\/10.1016\/j.jaip.2021.02.020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR46","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","volume":"148","author":"KM Buchheit","year":"2021","unstructured":"Buchheit\u00a0KM et\u00a0al (2021) Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J\u00a0Allergy Clin Immunol 148:574\u2013584. https:\/\/doi.org\/10.1016\/j.jaci.2021.05.043","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","volume":"150","author":"KM Buchheit","year":"2022","unstructured":"Buchheit\u00a0KM et\u00a0al (2022) Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease. J\u00a0Allergy Clin Immunol 150:415\u2013424. https:\/\/doi.org\/10.1016\/j.jaci.2022.04.007","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR48","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.jaip.2022.06.016","volume":"10","author":"M Taniguchi","year":"2022","unstructured":"Taniguchi\u00a0M et\u00a0al (2022) The role of omalizumab in NSAID-exacerbated respiratory disease: a\u00a0narrative review. J\u00a0Allergy Clin Immunol Pract 10:2570\u20132578. https:\/\/doi.org\/10.1016\/j.jaip.2022.06.016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR49","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/all.15650","volume":"78","author":"P Gevaert","year":"2023","unstructured":"Gevaert\u00a0P et\u00a0al (2023) European academy of allergy and clinical immunology position paper on endoscopic scoring of nasal polyposis. Allergy 78:912\u2013922. https:\/\/doi.org\/10.1111\/all.15650","journal-title":"Allergy"},{"key":"1635_CR50","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert\u00a0C et\u00a0al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase\u00a03\u00a0trials. Lancet 394:1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"key":"1635_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert\u00a0C et\u00a0al (2016) Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a\u00a0randomized clinical trial. JAMA 315:469\u2013479. https:\/\/doi.org\/10.1001\/jama.2015.19330","journal-title":"JAMA"},{"key":"1635_CR52","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"Bachert\u00a0C et\u00a0al (2017) Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J\u00a0Allergy Clin Immunol 140:1024\u20131031e.14. https:\/\/doi.org\/10.1016\/j.jaci.2017.05.044","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert\u00a0P et\u00a0al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J\u00a0Allergy Clin Immunol 131:110\u2013116.e11. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.047","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert\u00a0P et\u00a0al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase\u00a03\u00a0trials. J\u00a0Allergy Clin Immunol 146:595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR55","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"P Gevaert","year":"2011","unstructured":"Gevaert\u00a0P et\u00a0al (2011) Mepolizumab, a\u00a0humanized anti-IL\u20115 mAb, as a\u00a0treatment option for severe nasal polyposis. J\u00a0Allergy Clin Immunol 128:989\u2013995.e1\u20118. https:\/\/doi.org\/10.1016\/j.jaci.2011.07.056","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.anl.2022.11.004","volume":"50","author":"Y Iino","year":"2023","unstructured":"Iino\u00a0Y (2023) Eosinophilic otitis media; state-of-the-art diagnosis and treatment. Auris Nasus Larynx 50:479\u2013489. https:\/\/doi.org\/10.1016\/j.anl.2022.11.004","journal-title":"Auris Nasus Larynx"},{"key":"1635_CR57","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","volume":"34","author":"C Hopkins","year":"2009","unstructured":"Hopkins\u00a0C, Gillett\u00a0S, Slack\u00a0R, Lund\u00a0VJ, Browne\u00a0JP (2009) Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol 34:447\u2013454. https:\/\/doi.org\/10.1111\/j.1749-4486.2009.01995.x","journal-title":"Clin Otolaryngol"},{"key":"1635_CR58","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1007\/s00405-021-07019-6","volume":"279","author":"T Albrecht","year":"2022","unstructured":"Albrecht\u00a0T et\u00a0al (2022) Cross-cultural adaptation and validation of the 22-item sinonasal outcome test (SNOT-22) in German-speaking patients: a\u00a0prospective, multicenter cohort study. Eur Arch Otorhinolaryngol 279:2433\u20132439. https:\/\/doi.org\/10.1007\/s00405-021-07019-6","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1635_CR59","doi-asserted-by":"publisher","first-page":"110316","DOI":"10.1016\/j.jpsychores.2020.110316","volume":"140","author":"D Riedl","year":"2021","unstructured":"Riedl\u00a0D et\u00a0al (2021) Assessment of health-related quality-of-life in patients with chronic Rhinosinusitis\u2014Validation of the German Sino-Nasal Outcome Test-22 (German-SNOT-22). J\u00a0Psychosom Res 140:110316. https:\/\/doi.org\/10.1016\/j.jpsychores.2020.110316","journal-title":"J Psychosom Res"},{"key":"1635_CR60","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han\u00a0JK et\u00a0al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet Respir Med 9:1141\u20131153. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7","journal-title":"Lancet Respir Med"},{"key":"1635_CR61","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/archotol.1997.01900110025004","volume":"123","author":"MS Benninger","year":"1997","unstructured":"Benninger\u00a0MS, Senior\u00a0BA (1997) The development of the rhinosinusitis disability index. Arch Otolaryngol Head Neck Surg 123:1175\u20131179. https:\/\/doi.org\/10.1001\/archotol.1997.01900110025004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"1635_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2500\/105065801781329428","volume":"15","author":"BA Senior","year":"2001","unstructured":"Senior\u00a0BA, Glaze\u00a0C, Benninger\u00a0MS (2001) Use of the Rhinosinusitis Disability Index (RSDI) in rhinologic disease. Am J Rhinol 15:15\u201320. https:\/\/doi.org\/10.2500\/105065801781329428","journal-title":"Am J Rhinol"},{"key":"1635_CR63","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.otohns.2003.09.016","volume":"130","author":"MG Stewart","year":"2004","unstructured":"Stewart\u00a0MG et\u00a0al (2004) Development and validation of the Nasal Obstruction Symptom Evaluation (NOSE) scale. Otolaryngol Head Neck Surg 130:157\u2013163. https:\/\/doi.org\/10.1016\/j.otohns.2003.09.016","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1635_CR64","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0091-6749(99)70380-5","volume":"104","author":"EF Juniper","year":"1999","unstructured":"Juniper\u00a0EF, Thompson\u00a0AK, Ferrie\u00a0PJ, Roberts\u00a0JN (1999) Validation of the standardized version of the rhinoconjunctivitis quality of life questionnaire. J\u00a0Allergy Clin Immunol 104:364\u2013369. https:\/\/doi.org\/10.1016\/s0091-6749(99)70380-5","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR65","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1046\/j.1365-2222.2000.00668.x","volume":"30","author":"EF Juniper","year":"2000","unstructured":"Juniper\u00a0EF, Thompson\u00a0AK, Ferrie\u00a0PJ, Roberts\u00a0JN (2000) Development and validation of the mini rhinoconjunctivitis quality of life questionnaire. Clin Exp Allergy 30:132\u2013140. https:\/\/doi.org\/10.1046\/j.1365-2222.2000.00668.x","journal-title":"Clin Exp Allergy"},{"key":"1635_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s40629-016-0006-7","volume":"26","author":"L Klimek","year":"2017","unstructured":"Klimek\u00a0L et\u00a0al (2017) Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int 26:16\u201324. https:\/\/doi.org\/10.1007\/s40629-016-0006-7","journal-title":"Allergo J Int"},{"key":"1635_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhino12.000","volume":"50","author":"WJ Fokkens","year":"2012","unstructured":"Fokkens\u00a0WJ et\u00a0al (2012) EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A\u00a0summary for otorhinolaryngologists. Rhinology 50:1\u201312. https:\/\/doi.org\/10.4193\/Rhino12.000","journal-title":"Rhinology"},{"key":"1635_CR68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13601-019-0269-4","volume":"9","author":"L Calus","year":"2019","unstructured":"Calus\u00a0L et\u00a0al (2019) Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clin Transl Allergy 9:30. https:\/\/doi.org\/10.1186\/s13601-019-0269-4","journal-title":"Clin Transl Allergy"},{"key":"1635_CR69","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/0194599813517080","volume":"150","author":"K Snidvongs","year":"2014","unstructured":"Snidvongs\u00a0K, Heller\u00a0GZ, Sacks\u00a0R, Harvey\u00a0RJ (2014) Validity of European position paper on rhinosinusitis disease control assessment and modifications in chronic rhinosinusitis. Otolaryngol Head Neck Surg 150:479\u2013486. https:\/\/doi.org\/10.1177\/0194599813517080","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1635_CR70","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/all.12983","volume":"72","author":"J van der Veen","year":"2017","unstructured":"van der Veen\u00a0J et\u00a0al (2017) Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a\u00a0tertiary referral centre. Allergy 72:282\u2013290. https:\/\/doi.org\/10.1111\/all.12983","journal-title":"Allergy"},{"key":"1635_CR71","doi-asserted-by":"publisher","first-page":"103701","DOI":"10.1016\/j.amjoto.2022.103701","volume":"44","author":"M Gelardi","year":"2023","unstructured":"Gelardi\u00a0M et\u00a0al (2023) Correlation between chronic rhinosinusitis with nasal polyposis (CRSwNP) severity and asthma control. Am J Otolaryngol 44:103701. https:\/\/doi.org\/10.1016\/j.amjoto.2022.103701","journal-title":"Am J Otolaryngol"},{"key":"1635_CR72","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","volume":"113","author":"RA Nathan","year":"2004","unstructured":"Nathan\u00a0RA et\u00a0al (2004) Development of the asthma control test: a\u00a0survey for assessing asthma control. J\u00a0Allergy Clin Immunol 113:59\u201365. https:\/\/doi.org\/10.1016\/j.jaci.2003.09.008","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR73","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1067\/mhn.2001.119324","volume":"125","author":"N Ashraf","year":"2001","unstructured":"Ashraf\u00a0N, Bhattacharyya\u00a0N (2001) Determination of the \u201eincidental\u201c Lund score for the staging of chronic rhinosinusitis. Otolaryngol Head Neck Surg 125:483\u2013486. https:\/\/doi.org\/10.1067\/mhn.2001.119324","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1635_CR74","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.otohns.2007.02.004","volume":"137","author":"C Hopkins","year":"2007","unstructured":"Hopkins\u00a0C, Browne\u00a0JP, Slack\u00a0R, Lund\u00a0V, Brown\u00a0P (2007) The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg 137:555\u2013561. https:\/\/doi.org\/10.1016\/j.otohns.2007.02.004","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1635_CR75","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0194-59989770005-6","volume":"117","author":"VJ Lund","year":"1997","unstructured":"Lund\u00a0VJ, Kennedy\u00a0DW (1997) Staging for rhinosinusitis. Otolaryngol Head Neck Surg 117:S35\u2013S40. https:\/\/doi.org\/10.1016\/S0194-59989770005-6","journal-title":"Otolaryngol Head Neck Surg"},{"key":"1635_CR76","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-020-00218-1","volume":"6","author":"C Bachert","year":"2020","unstructured":"Bachert\u00a0C et\u00a0al (2020) Adult chronic rhinosinusitis. Nat Rev Dis Primers 6:86. https:\/\/doi.org\/10.1038\/s41572-020-00218-1","journal-title":"Nat Rev Dis Primers"},{"key":"1635_CR77","first-page":"222","volume":"34","author":"G Kobal","year":"1996","unstructured":"Kobal\u00a0G et\u00a0al (1996) \u201eSniffin\u2019 sticks\u201c: screening of olfactory performance. Rhinology 34:222\u2013226","journal-title":"Rhinology"},{"key":"1635_CR78","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00405-018-5248-1","volume":"276","author":"A Oleszkiewicz","year":"2019","unstructured":"Oleszkiewicz\u00a0A, Schriever\u00a0VA, Croy\u00a0I, Hahner\u00a0A, Hummel\u00a0T (2019) Updated Sniffin\u2019 Sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol 276:719\u2013728. https:\/\/doi.org\/10.1007\/s00405-018-5248-1","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1635_CR79","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5414\/ALX02331E","volume":"6","author":"O Pfaar","year":"2022","unstructured":"Pfaar\u00a0O et\u00a0al (2022) Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (OGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD). Allergol 6:167\u2013232. https:\/\/doi.org\/10.5414\/ALX02331E","journal-title":"Allergol"},{"key":"1635_CR80","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/alr.23319","volume":"14","author":"E De Corso","year":"2024","unstructured":"De Corso\u00a0E et\u00a0al (2024) Correlation between inflammatory biomarkers and disease control in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 14:1195\u20131205. https:\/\/doi.org\/10.1002\/alr.23319","journal-title":"Int Forum Allergy Rhinol"},{"key":"1635_CR81","doi-asserted-by":"publisher","first-page":"1143351","DOI":"10.3389\/fmed.2023.1143351","volume":"10","author":"M Gelardi","year":"2023","unstructured":"Gelardi\u00a0M, Giancaspro\u00a0R, Cassano\u00a0M, Ribatti\u00a0D (2023) Nasal cytology and histology in CRSwNP: Two sides of the same coin. Front Med 10:1143351. https:\/\/doi.org\/10.3389\/fmed.2023.1143351","journal-title":"Front Med"},{"key":"1635_CR82","doi-asserted-by":"publisher","first-page":"737086","DOI":"10.3389\/falgy.2021.737086","volume":"2","author":"KS Huntley","year":"2021","unstructured":"Huntley\u00a0KS, Raber\u00a0J, Fine\u00a0L, Bernstein\u00a0JA (2021) Influence of the microbiome on chronic rhinosinusitis with and without polyps: an evolving discussion. Front Allergy 2:737086. https:\/\/doi.org\/10.3389\/falgy.2021.737086","journal-title":"Front Allergy"},{"key":"1635_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011996.pub2","author":"LY Chong","year":"2016","unstructured":"Chong\u00a0LY et\u00a0al (2016) Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011996.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1635_CR84","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/alr.21096","volume":"3","author":"L Rudmik","year":"2013","unstructured":"Rudmik\u00a0L et\u00a0al (2013) Topical therapies in the management of chronic rhinosinusitis: an evidence-based review with recommendations. Int Forum Allergy Rhinol 3:281\u2013298. https:\/\/doi.org\/10.1002\/alr.21096","journal-title":"Int Forum Allergy Rhinol"},{"key":"1635_CR85","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/lary.24066","volume":"123","author":"CC Wei","year":"2013","unstructured":"Wei\u00a0CC, Adappa\u00a0ND, Cohen\u00a0NA (2013) Use of topical nasal therapies in the management of chronic rhinosinusitis. Laryngoscope 123:2347\u20132359. https:\/\/doi.org\/10.1002\/lary.24066","journal-title":"Laryngoscope"},{"key":"1635_CR86","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/lary.24937","volume":"125","author":"G Reychler","year":"2015","unstructured":"Reychler\u00a0G et\u00a0al (2015) Effect of three-drug delivery modalities on olfactory function in chronic sinusitis. Laryngoscope 125:549\u2013555. https:\/\/doi.org\/10.1002\/lary.24937","journal-title":"Laryngoscope"},{"key":"1635_CR87","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jaci.2014.10.018","volume":"135","author":"C Wang","year":"2015","unstructured":"Wang\u00a0C et\u00a0al (2015) Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J\u00a0Allergy Clin Immunol 135:922\u2013929.e26. https:\/\/doi.org\/10.1016\/j.jaci.2014.10.018","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR88","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/alr.20024","volume":"1","author":"D Lal","year":"2011","unstructured":"Lal\u00a0D, Hwang\u00a0PH (2011) Oral corticosteroid therapy in chronic rhinosinusitis without polyposis: a\u00a0systematic review. Int Forum Allergy Rhinol 1:136\u2013143. https:\/\/doi.org\/10.1002\/alr.20024","journal-title":"Int Forum Allergy Rhinol"},{"key":"1635_CR89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2310\/7750.2008.07029","volume":"12","author":"RN Richards","year":"2008","unstructured":"Richards\u00a0RN (2008) Side effects of short-term oral corticosteroids. J\u00a0Cutan Med Surg 12:77\u201381. https:\/\/doi.org\/10.2310\/7750.2008.07029","journal-title":"J Cutan Med Surg"},{"key":"1635_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-019-0303-6","volume":"10","author":"V Hox","year":"2020","unstructured":"Hox\u00a0V et\u00a0al (2020) Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy 10:1. https:\/\/doi.org\/10.1186\/s13601-019-0303-6","journal-title":"Clin Transl Allergy"},{"key":"1635_CR91","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1016\/j.jaip.2023.08.015","volume":"11","author":"G Chupp","year":"2023","unstructured":"Chupp\u00a0G et\u00a0al (2023) Mepolizumab reduces systemic corticosteroid use in chronic rhinosinusitis with nasal polyps. J\u00a0Allergy Clin Immunol Pract 11:3504\u20133512.e2. https:\/\/doi.org\/10.1016\/j.jaip.2023.08.015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR92","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4193\/Rhin20.415","volume":"59","author":"M Desrosiers","year":"2021","unstructured":"Desrosiers\u00a0M et\u00a0al (2021) Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology 59:301\u2013311. https:\/\/doi.org\/10.4193\/Rhin20.415","journal-title":"Rhinology"},{"key":"1635_CR93","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/alr.22281","volume":"9","author":"Z Huang","year":"2019","unstructured":"Huang\u00a0Z, Zhou\u00a0B (2019) Clarithromycin for the treatment of adult chronic rhinosinusitis: a\u00a0systematic review and meta-analysis. Int Forum Allergy Rhinol 9:545\u2013555. https:\/\/doi.org\/10.1002\/alr.22281","journal-title":"Int Forum Allergy Rhinol"},{"key":"1635_CR94","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.21037\/jtd.2018.10.41","volume":"10","author":"S Shen","year":"2018","unstructured":"Shen\u00a0S, Lou\u00a0H, Wang\u00a0C, Zhang\u00a0L (2018) Macrolide antibiotics in the treatment of chronic rhinosinusitis: evidence from a\u00a0meta-analysis. J\u00a0Thorac Dis 10:5913\u20135923. https:\/\/doi.org\/10.21037\/jtd.2018.10.41","journal-title":"J Thorac Dis"},{"key":"1635_CR95","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.clim.2015.05.012","volume":"160","author":"H Esmaeilzadeh","year":"2015","unstructured":"Esmaeilzadeh\u00a0H et\u00a0al (2015) Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a\u00a0randomized double-blind placebo-controlled trial. Clin Immunol 160:349\u2013357. https:\/\/doi.org\/10.1016\/j.clim.2015.05.012","journal-title":"Clin Immunol"},{"key":"1635_CR96","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/all.12131","volume":"68","author":"K Fruth","year":"2013","unstructured":"Fruth\u00a0K et\u00a0al (2013) Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy 68:659\u2013665. https:\/\/doi.org\/10.1111\/all.12131","journal-title":"Allergy"},{"key":"1635_CR97","first-page":"1639","volume":"16","author":"N Mortazavi","year":"2017","unstructured":"Mortazavi\u00a0N et\u00a0al (2017) Clinical and immunological efficacy of Aspirin desensitization in nasal polyp patients with Aspirin-exacerbated respiratory disease. Iran J Pharm Res 16:1639\u20131647","journal-title":"Iran J Pharm Res"},{"key":"1635_CR98","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","volume":"134","author":"M Swierczynska-Krepa","year":"2014","unstructured":"Swierczynska-Krepa\u00a0M et\u00a0al (2014) Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a\u00a0double-blind study. J\u00a0Allergy Clin Immunol 134:883\u2013890. https:\/\/doi.org\/10.1016\/j.jaci.2014.02.041","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR99","first-page":"291","volume":"43","author":"ML Barnes","year":"2005","unstructured":"Barnes\u00a0ML, Biallosterski\u00a0BT, Gray\u00a0RD, Fardon\u00a0TC, Lipworth\u00a0BJ (2005) Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. Rhinology 43:291\u2013295","journal-title":"Rhinology"},{"key":"1635_CR100","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/00016489509133350","volume":"115","author":"P Graf","year":"1995","unstructured":"Graf\u00a0P, Hallen\u00a0H, Juto\u00a0JE (1995) Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity. Acta Otolaryngol 115:71\u201375. https:\/\/doi.org\/10.3109\/00016489509133350","journal-title":"Acta Otolaryngol"},{"key":"1635_CR101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1017\/S002221511700192X","volume":"132","author":"K Seresirikachorn","year":"2018","unstructured":"Seresirikachorn\u00a0K, Khattiyawittayakun\u00a0L, Chitsuthipakorn\u00a0W, Snidvongs\u00a0K (2018) Antihistamines for treating rhinosinusitis: systematic review and meta-analysis of randomised controlled studies. J\u00a0Laryngol Otol 132:105\u2013110. https:\/\/doi.org\/10.1017\/S002221511700192X","journal-title":"J Laryngol Otol"},{"key":"1635_CR102","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1017\/s0022215100142422","volume":"112","author":"R Haye","year":"1998","unstructured":"Haye\u00a0R, Aanesen\u00a0JP, Burtin\u00a0B, Donnelly\u00a0F, Duby\u00a0C (1998) The effect of cetirizine on symptoms and signs of nasal polyposis. J\u00a0Laryngol Otol 112:1042\u20131046. https:\/\/doi.org\/10.1017\/s0022215100142422","journal-title":"J Laryngol Otol"},{"key":"1635_CR103","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2500\/ajra.2013.27.3976","volume":"27","author":"JL Wentzel","year":"2013","unstructured":"Wentzel\u00a0JL et\u00a0al (2013) Leukotriene antagonists in nasal polyposis: a\u00a0meta-analysis and systematic review. am j rhinol allergy 27:482\u2013489. https:\/\/doi.org\/10.2500\/ajra.2013.27.3976","journal-title":"am j rhinol allergy"},{"key":"1635_CR104","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/lary.26989","volume":"128","author":"L Van Gerven","year":"2018","unstructured":"Van Gerven\u00a0L et\u00a0al (2018) Lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps. Laryngoscope 128:1743\u20131751. https:\/\/doi.org\/10.1002\/lary.26989","journal-title":"Laryngoscope"},{"key":"1635_CR105","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/lary.27815","volume":"129","author":"S Alsharif","year":"2019","unstructured":"Alsharif\u00a0S et\u00a0al (2019) Endoscopic sinus surgery for type-2\u00a0CRS wNP: an endotype-based retrospective study. Laryngoscope 129:1286\u20131292. https:\/\/doi.org\/10.1002\/lary.27815","journal-title":"Laryngoscope"},{"key":"1635_CR106","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert\u00a0C et\u00a0al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J\u00a0Allergy Clin Immunol 147:29\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR107","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens\u00a0WJ et\u00a0al (2023) EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 61:194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489","journal-title":"Rhinology"},{"key":"1635_CR108","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4193\/Rhin23.415","volume":"62","author":"WJ Fokkens","year":"2024","unstructured":"Fokkens\u00a0WJ et\u00a0al (2024) EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology 62:287\u2013298. https:\/\/doi.org\/10.4193\/Rhin23.415","journal-title":"Rhinology"},{"key":"1635_CR109","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1055\/a-1197-0136","volume":"99","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L et\u00a0al (2020) Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem. Laryngorhinootologie 99:511\u2013527. https:\/\/doi.org\/10.1055\/a-1197-0136","journal-title":"Laryngorhinootologie"},{"key":"1635_CR110","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s15007-022-5080-1","volume":"31","author":"L Klimek","year":"2022","unstructured":"Klimek\u00a0L et\u00a0al (2022) Dokumentation von Biologika-Therapien bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP): Dupilumab, Omalizumab und Mepolizumab. Allergo\u00a0J 31:24\u201339. https:\/\/doi.org\/10.1007\/s15007-022-5080-1","journal-title":"Allergo J"},{"key":"1635_CR111","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt\u00a0A et\u00a0al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a\u00a01-year, randomised, double-blinded, placebo-controlled, phase\u00a03\u00a0trial. Lancet 389:2287\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1","journal-title":"Lancet"},{"key":"1635_CR112","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","volume":"35","author":"WW Busse","year":"2018","unstructured":"Busse\u00a0WW et\u00a0al (2018) Liberty asthma QUEST: phase\u00a03 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 35:737\u2013748. https:\/\/doi.org\/10.1007\/s12325-018-0702-4","journal-title":"Adv Ther"},{"key":"1635_CR113","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro\u00a0M et\u00a0al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N\u00a0Engl J Med 378:2486\u20132496. https:\/\/doi.org\/10.1056\/NEJMoa1804092","journal-title":"N Engl J Med"},{"key":"1635_CR114","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1055\/a-1908-3074","volume":"101","author":"L Klimek","year":"2022","unstructured":"Klimek\u00a0L et\u00a0al (2022) Empfehlungen zur Uberprufung der Wirksamkeit und Verlaufsdokumentation von Dupilumab bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) im deutschen Gesundheitssystem. Laryngorhinootologie 101:855\u2013865. https:\/\/doi.org\/10.1055\/a-1908-3074","journal-title":"Laryngorhinootologie"},{"key":"1635_CR115","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1055\/a-1200-1830","volume":"99","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L et\u00a0al (2020) Elevated eosinophil count associated with Dupilumab therapy in patients with type\u20112 inflammation. Laryngorhinootologie 99:811\u2013812. https:\/\/doi.org\/10.1055\/a-1200-1830","journal-title":"Laryngorhinootologie"},{"key":"1635_CR116","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe\u00a0KF et\u00a0al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N\u00a0Engl J Med 378:2475\u20132485. https:\/\/doi.org\/10.1056\/NEJMoa1804093","journal-title":"N Engl J Med"},{"key":"1635_CR117","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12348-020-00234-y","volume":"11","author":"A Kimura","year":"2021","unstructured":"Kimura\u00a0A, Takeda\u00a0A, Ikebukuro\u00a0T, Hori\u00a0J (2021) Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J\u00a0Ophthalmic Inflamm Infect 11:3. https:\/\/doi.org\/10.1186\/s12348-020-00234-y","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1635_CR118","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler\u00a0ME et\u00a0al (2022) Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic Esophagitis. J\u00a0Allergy Clin Immunol Pract 10:2695\u20132709. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR119","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4193\/Rhin22.129","volume":"60","author":"BR Haxel","year":"2022","unstructured":"Haxel\u00a0BR et\u00a0al (2022) Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology 60:435\u2013443. https:\/\/doi.org\/10.4193\/Rhin22.129","journal-title":"Rhinology"},{"key":"1635_CR120","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.waojou.2023.100780","volume":"16","author":"T Albrecht","year":"2023","unstructured":"Albrecht\u00a0T et\u00a0al (2023) Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1\u00a0year of therapy. World Allergy Organ\u00a0J 16:100780. https:\/\/doi.org\/10.1016\/j.waojou.2023.100780","journal-title":"World Allergy Organ J"},{"key":"1635_CR121","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/all.15772","volume":"78","author":"E De Corso","year":"2023","unstructured":"De Corso\u00a0E et\u00a0al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a\u00a0multicentric observational phase\u00a0IV real-life study (DUPIREAL). Allergy 78:2669\u20132683. https:\/\/doi.org\/10.1111\/all.15772","journal-title":"Allergy"},{"key":"1635_CR122","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1111\/all.16263","volume":"79","author":"P Huber","year":"2024","unstructured":"Huber\u00a0P et\u00a0al (2024) Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3\u00a0years. Allergy 79:3108\u20133117. https:\/\/doi.org\/10.1111\/all.16263","journal-title":"Allergy"},{"key":"1635_CR123","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00405-022-07679-y","volume":"280","author":"F Jansen","year":"2023","unstructured":"Jansen\u00a0F et\u00a0al (2023) Dupilumab (Dupixent((R))) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a\u00a0single-centered, retrospective single-arm longitudinal study from a\u00a0university hospital in Germany. Eur Arch Otorhinolaryngol 280:1741\u20131755. https:\/\/doi.org\/10.1007\/s00405-022-07679-y","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1635_CR124","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/coa.14172","volume":"49","author":"E De Corso","year":"2024","unstructured":"De Corso\u00a0E et\u00a0al (2024) Comparative real-world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients. Clin Otolaryngol 49:481\u2013489. https:\/\/doi.org\/10.1111\/coa.14172","journal-title":"Clin Otolaryngol"},{"key":"1635_CR125","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/19458924241272978","volume":"38","author":"DH Kim","year":"2024","unstructured":"Kim\u00a0DH, Stybayeva\u00a0G, Hwang\u00a0SH (2024) Comparative effectiveness of dupilumab versus sinus surgery for chronic rhinosinusitis with polyps: systematic review and a\u00a0meta-analysis. am j rhinol allergy 38:428\u2013436. https:\/\/doi.org\/10.1177\/19458924241272978","journal-title":"am j rhinol allergy"},{"key":"1635_CR126","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","volume":"78","author":"RJL van der Lans","year":"2023","unstructured":"van der Lans\u00a0RJL et\u00a0al (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6\u00a0months. Allergy 78:2684\u20132697. https:\/\/doi.org\/10.1111\/all.15796","journal-title":"Allergy"},{"key":"1635_CR127","doi-asserted-by":"publisher","DOI":"10.1055\/a-2039-1831","author":"S Becker","year":"2023","unstructured":"Becker\u00a0S et\u00a0al (2023) Positionspapier: ICD-Codierung der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) im ICD-10-GM als Grundlage fur eine Therapie mit Biologika. Laryngorhinootologie. https:\/\/doi.org\/10.1055\/a-2039-1831","journal-title":"Laryngorhinootologie"},{"key":"1635_CR128","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","volume":"158","author":"DW MacGlashan Jr.","year":"1997","unstructured":"MacGlashan\u00a0DW Jr. et\u00a0al (1997) Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J\u00a0Immunol 158:1438\u20131445","journal-title":"J Immunol"},{"key":"1635_CR129","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","volume":"151","author":"LG Presta","year":"1993","unstructured":"Presta\u00a0LG et\u00a0al (1993) Humanization of an antibody directed against IgE. J\u00a0Immunol 151:2623\u20132632","journal-title":"J Immunol"},{"key":"1635_CR130","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","volume":"60","author":"M Humbert","year":"2005","unstructured":"Humbert\u00a0M et\u00a0al (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step\u00a04\u00a0treatment): INNOVATE. Allergy 60:309\u2013316. https:\/\/doi.org\/10.1111\/j.1398-9995.2004.00772.x","journal-title":"Allergy"},{"key":"1635_CR131","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer\u00a0M et\u00a0al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N\u00a0Engl J Med 368:924\u2013935. https:\/\/doi.org\/10.1056\/NEJMoa1215372","journal-title":"N Engl J Med"},{"key":"1635_CR132","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaip.2022.10.022","volume":"11","author":"M Groetch","year":"2023","unstructured":"Groetch\u00a0M et\u00a0al (2023) Retail food equivalents for post-oral immunotherapy dosing in the omalizumab as monotherapy and as adjunct therapy to multi-allergen oral immunotherapy in food-allergic children and adults (OutMATCH) clinical trial. J\u00a0Allergy Clin Immunol Pract 11:572\u2013580.e2. https:\/\/doi.org\/10.1016\/j.jaip.2022.10.022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR133","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1055\/s-0043-102070","volume":"71","author":"M Lommatzsch","year":"2017","unstructured":"Lommatzsch\u00a0M, Geissler\u00a0K, Bergmann\u00a0KC, Virchow\u00a0JC (2017) IgE and Anti-IgE in asthma: a\u00a0chequered history. Pneumologie 71:398\u2013405. https:\/\/doi.org\/10.1055\/s-0043-102070","journal-title":"Pneumologie"},{"key":"1635_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.11.005","author":"T Pongdee","year":"2024","unstructured":"Pongdee\u00a0T, Li\u00a0JT (2024) Omalizumab safety concerns. J\u00a0Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2024.11.005","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR135","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","volume":"145","author":"JA Namazy","year":"2020","unstructured":"Namazy\u00a0JA et\u00a0al (2020) Pregnancy outcomes in the omalizumab pregnancy registry and a\u00a0disease-matched comparator cohort. J\u00a0Allergy Clin Immunol 145:528\u2013536.e1. https:\/\/doi.org\/10.1016\/j.jaci.2019.05.019","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051025","author":"U Foerster-Ruhrmann","year":"2024","unstructured":"Foerster-Ruhrmann\u00a0U et\u00a0al (2024) Biologics reduce symptoms of alcohol intolerance better than aspirin desensitization in patients with N\u2011ERD and nasal polyps. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12051025","journal-title":"Biomedicines"},{"key":"1635_CR137","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","volume":"149","author":"P Gevaert","year":"2022","unstructured":"Gevaert\u00a0P et\u00a0al (2022) Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J\u00a0Allergy Clin Immunol 149:957\u2013965.e3. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.045","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR138","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00106-024-01433-y","volume":"72","author":"AR Staufenberg","year":"2024","unstructured":"Staufenberg\u00a0AR et\u00a0al (2024) Biologic therapy in patients with severe NSAID-exacerbated respiratory disease and previous aspirin desensitization : results of a\u00a0multicentric study. HNO 72:473\u2013483. https:\/\/doi.org\/10.1007\/s00106-024-01433-y","journal-title":"HNO"},{"key":"1635_CR139","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1055\/a-1644-4066","volume":"100","author":"L Klimek","year":"2021","unstructured":"Klimek\u00a0L et\u00a0al (2021) Empfehlungen zur Anwendung von Omalizumab bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem. Laryngorhinootologie 100:952\u2013963. https:\/\/doi.org\/10.1055\/a-1644-4066","journal-title":"Laryngorhinootologie"},{"key":"1635_CR140","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40265-015-0513-8","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating\u00a0GM (2015) Mepolizumab: first global approval. Drugs 75:2163\u20132169. https:\/\/doi.org\/10.1007\/s40265-015-0513-8","journal-title":"Drugs"},{"key":"1635_CR141","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord\u00a0ID et\u00a0al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a\u00a0multicentre, double-blind, placebo-controlled trial. Lancet 380:651\u2013659. https:\/\/doi.org\/10.1016\/S0140-6736(12)60988-X","journal-title":"Lancet"},{"key":"1635_CR142","doi-asserted-by":"publisher","first-page":"175346661880849","DOI":"10.1177\/1753466618808490","volume":"12","author":"R Emma","year":"2018","unstructured":"Emma\u00a0R, Morjaria\u00a0JB, Fuochi\u00a0V, Polosa\u00a0R, Caruso\u00a0M (2018) Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis 12:1753466618808490. https:\/\/doi.org\/10.1177\/1753466618808490","journal-title":"Ther Adv Respir Dis"},{"key":"1635_CR143","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.anai.2024.06.033","volume":"133","author":"JA Bernstein","year":"2024","unstructured":"Bernstein\u00a0JA et\u00a0al (2024) Real-world unified airway benefits of mepolizumab: Effectiveness in patients with asthma and comorbid nasal polyps. Ann Allergy Asthma Immunol 133:422\u2013429.e2. https:\/\/doi.org\/10.1016\/j.anai.2024.06.033","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1635_CR144","doi-asserted-by":"publisher","first-page":"104329","DOI":"10.1016\/j.amjoto.2024.104329","volume":"45","author":"C Galletti","year":"2024","unstructured":"Galletti\u00a0C et\u00a0al (2024) Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: real life data in a\u00a0tertiary care. Am J Otolaryngol 45:104329. https:\/\/doi.org\/10.1016\/j.amjoto.2024.104329","journal-title":"Am J Otolaryngol"},{"key":"1635_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.otoeng.2024.08.001","author":"J Maza-Solano","year":"2024","unstructured":"Maza-Solano\u00a0J et\u00a0al (2024) Real-world outcomes on quality-of-life improvement in patients with nasal polyposis treated with mepolizumab. RINOSUR study. Acta Otorrinolaringol Esp. https:\/\/doi.org\/10.1016\/j.otoeng.2024.08.001","journal-title":"Acta Otorrinolaringol Esp"},{"key":"1635_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020485","author":"MS Dominguez-Sosa","year":"2023","unstructured":"Dominguez-Sosa\u00a0MS et\u00a0al (2023) Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines11020485","journal-title":"Biomedicines"},{"key":"1635_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12081304","author":"S Gallo","year":"2022","unstructured":"Gallo\u00a0S et\u00a0al (2022) Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a\u00a0multicentric real-life study. J\u00a0Pers Med. https:\/\/doi.org\/10.3390\/jpm12081304","journal-title":"J Pers Med"},{"key":"1635_CR148","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1016\/j.jaip.2024.09.021","volume":"12","author":"KM Buchheit","year":"2024","unstructured":"Buchheit\u00a0KM et\u00a0al (2024) Efficacy of biologics in NSAID-ERD: united airways from the nose to the bronchi. J\u00a0Allergy Clin Immunol Pract 12:2917\u20132932. https:\/\/doi.org\/10.1016\/j.jaip.2024.09.021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR149","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/lary.31305","volume":"134","author":"M Dorling","year":"2024","unstructured":"Dorling\u00a0M et\u00a0al (2024) Real-world adverse events after type\u00a02 biologic use in chronic rhinosinusitis with nasal polyps. Laryngoscope 134:3054\u20133059. https:\/\/doi.org\/10.1002\/lary.31305","journal-title":"Laryngoscope"},{"key":"1635_CR150","doi-asserted-by":"publisher","DOI":"10.1177\/19458924241280757","author":"D Gershnabel Milk","year":"2024","unstructured":"Gershnabel Milk\u00a0D, Lam\u00a0KK, Han\u00a0JK (2024) Postmarketing analysis of eosinophilic adverse reactions in the use of biologic therapies for type\u00a02 inflammatory conditions. am j rhinol allergy. https:\/\/doi.org\/10.1177\/19458924241280757","journal-title":"am j rhinol allergy"},{"key":"1635_CR151","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/a-2003-4730","volume":"102","author":"L Klimek","year":"2023","unstructured":"Klimek\u00a0L et\u00a0al (2023) Empfehlungen zur Uberprufung der Wirksamkeit und Verlaufsdokumentation von Mepolizumab bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) im deutschen Gesundheitssystem. Laryngorhinootologie 102:89\u201399. https:\/\/doi.org\/10.1055\/a-2003-4730","journal-title":"Laryngorhinootologie"},{"key":"1635_CR152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5414\/ALX02460E","volume":"8","author":"L Klimek","year":"2024","unstructured":"Klimek\u00a0L et\u00a0al (2024) Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): discontinue, change, continue therapy? Allergol Sel 8:26\u201339. https:\/\/doi.org\/10.5414\/ALX02460E","journal-title":"Allergol Sel"},{"key":"1635_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115972","author":"D Bagnasco","year":"2024","unstructured":"Bagnasco\u00a0D et\u00a0al (2024) Thymic stromal lymphopoietin and tezepelumab in airway diseases: from physiological role to target therapy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25115972","journal-title":"Int J Mol Sci"},{"key":"1635_CR154","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","volume":"21","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow\u00a0A et\u00a0al (2020) NAVIGATOR: a\u00a0phase\u00a03 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res 21:266. https:\/\/doi.org\/10.1186\/s12931-020-01526-6","journal-title":"Respir Res"},{"key":"1635_CR155","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12931-020-01541-7","volume":"21","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow\u00a0A et\u00a0al (2020) DESTINATION: a\u00a0phase\u00a03, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res 21:279. https:\/\/doi.org\/10.1186\/s12931-020-01541-7","journal-title":"Respir Res"},{"key":"1635_CR156","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03006-5","author":"JS Jacobs","year":"2024","unstructured":"Jacobs\u00a0JS et\u00a0al (2024) Effect of tezepelumab on Sino-nasal outcome test (SNOT)-22 domain and symptom-specific scores in patients with severe, uncontrolled asthma and a\u00a0history of chronic Rhinosinusitis with nasal polyps. Adv Ther. https:\/\/doi.org\/10.1007\/s12325-024-03006-5","journal-title":"Adv Ther"},{"key":"1635_CR157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414482","author":"BJ Lipworth","year":"2025","unstructured":"Lipworth\u00a0BJ et\u00a0al (2025) Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2414482","journal-title":"N Engl J Med"},{"key":"1635_CR158","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673","author":"DJ Jackson","year":"2024","unstructured":"Jackson\u00a0DJ et\u00a0al (2024) Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2406673","journal-title":"N Engl J Med"},{"key":"1635_CR159","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","volume":"405","author":"P Gevaert","year":"2025","unstructured":"Gevaert\u00a0P et\u00a0al (2025) Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR\u20111 and ANCHOR-2): phase\u00a03, randomised, double-blind, parallel trials. Lancet 405:911\u2013926. https:\/\/doi.org\/10.1016\/S0140-6736(25)00197-7","journal-title":"Lancet"},{"key":"1635_CR160","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert\u00a0C et\u00a0al (2022) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J\u00a0Allergy Clin Immunol 149:1309\u20131317.e2. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.030","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144247","author":"E Chiner","year":"2024","unstructured":"Chiner\u00a0E et\u00a0al (2024) Real-life clinical outcomes of benralizumab treatment in patients with uncontrolled severe asthma and coexisting chronic rhinosinusitis with nasal Polyposis. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm13144247","journal-title":"J Clin Med"},{"key":"1635_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14091014","author":"E De Corso","year":"2024","unstructured":"De Corso\u00a0E et\u00a0al (2024) Sinonasal outcomes obtained after 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and CRSwNP: a\u00a0\u201ereal-life\u201c observational study. J\u00a0Pers Med. https:\/\/doi.org\/10.3390\/jpm14091014","journal-title":"J Pers Med"},{"key":"1635_CR163","doi-asserted-by":"crossref","unstructured":"AstraZeneca (2024) Clical Trials Appendix, Q3 2024 Results Update, Seite\u00a088. https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2024\/9mq3\/9M-and-Q3-2024-results-clinical-trials-appendix.pdf","DOI":"10.1016\/j.fopow.2024.02.009"},{"key":"1635_CR164","doi-asserted-by":"publisher","first-page":"100343","DOI":"10.1016\/j.jacig.2024.100343","volume":"4","author":"P Bakakos","year":"2025","unstructured":"Bakakos\u00a0P et\u00a0al (2025) A\u00a0RESPONSE to anti-IL-5\u00a0therapy in comorbid patients with chronic rhinosinusitis with nasal polyps and severe asthma: study protocol. J\u00a0Allergy Clin Immunol Glob 4:100343. https:\/\/doi.org\/10.1016\/j.jacig.2024.100343","journal-title":"J Allergy Clin Immunol Glob"},{"key":"1635_CR165","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00085-2022","author":"S Siddiqui","year":"2022","unstructured":"Siddiqui\u00a0S et\u00a0al (2022) AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps. ERJ Open Res. https:\/\/doi.org\/10.1183\/23120541.00085-2022","journal-title":"ERJ Open Res"},{"key":"1635_CR166","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/TCRM.S467250","volume":"21","author":"HH Kariyawasam","year":"2025","unstructured":"Kariyawasam\u00a0HH, Langan\u00a0D, Rimmer\u00a0J (2025) Chronic rhinosinusitis with nasal polyps and biologics: a\u00a0call for better data standardisation and presentation in clinical studies. Ther Clin Risk Manag 21:27\u201334. https:\/\/doi.org\/10.2147\/TCRM.S467250","journal-title":"Ther Clin Risk Manag"},{"key":"1635_CR167","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","volume":"10","author":"S Cai","year":"2022","unstructured":"Cai\u00a0S, Xu\u00a0S, Lou\u00a0H, Zhang\u00a0L (2022) Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a\u00a0network analysis. J\u00a0Allergy Clin Immunol Pract 10:1876\u20131886.e77. https:\/\/doi.org\/10.1016\/j.jaip.2022.02.034","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR168","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.jaip.2024.09.015","volume":"12","author":"C Hopkins","year":"2024","unstructured":"Hopkins\u00a0C et\u00a0al (2024) Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison. J\u00a0Allergy Clin Immunol Pract 12:3393\u20133401.e15. https:\/\/doi.org\/10.1016\/j.jaip.2024.09.015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR169","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/alr.23234","volume":"14","author":"GX Papacharalampous","year":"2024","unstructured":"Papacharalampous\u00a0GX et\u00a0al (2024) Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A\u00a0systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy. Int Forum Allergy Rhinol 14:96\u2013109. https:\/\/doi.org\/10.1002\/alr.23234","journal-title":"Int Forum Allergy Rhinol"},{"key":"1635_CR170","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","volume":"9","author":"AT Peters","year":"2021","unstructured":"Peters\u00a0AT et\u00a0al (2021) Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps. J\u00a0Allergy Clin Immunol Pract 9:2461\u20132471.e65. https:\/\/doi.org\/10.1016\/j.jaip.2021.01.031","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR171","doi-asserted-by":"publisher","first-page":"e12169","DOI":"10.1002\/clt2.12169","volume":"12","author":"Y Shen","year":"2022","unstructured":"Shen\u00a0Y, Ke\u00a0X, Hong\u00a0S, Yang\u00a0Y (2022) Adverse events for biologics in patients with CRSwNP: a\u00a0meta-analysis. Clin Transl Allergy 12:e12169. https:\/\/doi.org\/10.1002\/clt2.12169","journal-title":"Clin Transl Allergy"},{"key":"1635_CR172","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00060-023-8567-9","volume":"53","author":"S Becker","year":"2023","unstructured":"Becker\u00a0S, Klimek\u00a0L (2023) Das deutsche CRS-Register \u2013 Eine herzliche Einladung zum Mitmachen! Hno Nachrichten 53:65\u201365. https:\/\/doi.org\/10.1007\/s00060-023-8567-9","journal-title":"Hno Nachrichten"},{"key":"1635_CR173","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5414\/ALX02475E","volume":"8","author":"J Hagemann","year":"2024","unstructured":"Hagemann\u00a0J et\u00a0al (2024) EGPA: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) as a\u00a0special presentation of chronic rhinosinusitis with nasal polyps (CRSwNP). Allergol Sel 8:18\u201325. https:\/\/doi.org\/10.5414\/ALX02475E","journal-title":"Allergol Sel"},{"key":"1635_CR174","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12931-018-0823-y","volume":"19","author":"CM Philpott","year":"2018","unstructured":"Philpott\u00a0CM et\u00a0al (2018) Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res 19:129. https:\/\/doi.org\/10.1186\/s12931-018-0823-y","journal-title":"Respir Res"},{"key":"1635_CR175","doi-asserted-by":"publisher","first-page":"761388","DOI":"10.3389\/falgy.2021.761388","volume":"2","author":"N Claeys","year":"2021","unstructured":"Claeys\u00a0N et\u00a0al (2021) Patients unmet needs in chronic rhinosinusitis with nasal polyps care: a\u00a0patient advisory board statement of EUFOREA. Front Allerg 2:761388. https:\/\/doi.org\/10.3389\/falgy.2021.761388","journal-title":"Front Allerg"},{"key":"1635_CR176","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/clt2.70010","volume":"15","author":"O Pfaar","year":"2025","unstructured":"Pfaar\u00a0O et\u00a0al (2025) Chronic rhinosinusitis with nasal polyps: key considerations in the multidisciplinary team approach. Clin Transl Allergy 15:e70010. https:\/\/doi.org\/10.1002\/clt2.70010","journal-title":"Clin Transl Allergy"},{"key":"1635_CR177","doi-asserted-by":"publisher","DOI":"10.1111\/all.16418","author":"S Toppila-Salmi","year":"2024","unstructured":"Toppila-Salmi\u00a0S et\u00a0al (2024) Endotyping in chronic rhinosinusitis\u2014an EAACI task force report. Allergy. https:\/\/doi.org\/10.1111\/all.16418","journal-title":"Allergy"},{"key":"1635_CR178","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.iac.2019.12.009","volume":"40","author":"DY Cho","year":"2020","unstructured":"Cho\u00a0DY, Hunter\u00a0RC, Ramakrishnan\u00a0VR (2020) The microbiome and chronic rhinosinusitis. Immunol Allergy Clin North Am 40:251\u2013263. https:\/\/doi.org\/10.1016\/j.iac.2019.12.009","journal-title":"Immunol Allergy Clin North Am"},{"key":"1635_CR179","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1177\/1945892420929270","volume":"34","author":"HN Kuhar","year":"2020","unstructured":"Kuhar\u00a0HN et\u00a0al (2020) Histopathologic influences of comorbid smoking status in chronic rhinosinusitis. Am J Rhinol Allergy 34:775\u2013783. https:\/\/doi.org\/10.1177\/1945892420929270","journal-title":"Am J Rhinol Allergy"},{"key":"1635_CR180","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/lio2.774","volume":"7","author":"EM Leland","year":"2022","unstructured":"Leland\u00a0EM, Vohra\u00a0V, Seal\u00a0SM, Zhang\u00a0Z, Ramanathan\u00a0M Jr. (2022) Environmental air pollution and chronic rhinosinusitis: a\u00a0systematic review. Laryngoscope Investig Otolaryngol 7:349\u2013360. https:\/\/doi.org\/10.1002\/lio2.774","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"1635_CR181","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082693","author":"SH Shin","year":"2020","unstructured":"Shin\u00a0SH, Ye\u00a0MK, Lee\u00a0DW, Chae\u00a0MH, Han\u00a0BD (2020) Nasal epithelial cells activated with alternaria and house dust mite induce not only th2 but also th1 immune responses. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21082693","journal-title":"Int J Mol Sci"},{"key":"1635_CR182","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032366","author":"SH Shin","year":"2023","unstructured":"Shin\u00a0SH, Ye\u00a0MK, Lee\u00a0DW, Geum\u00a0SY (2023) Immunopathologic role of fungi in chronic rhinosinusitis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24032366","journal-title":"Int J Mol Sci"},{"key":"1635_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13040715","author":"JJ Seah","year":"2023","unstructured":"Seah\u00a0JJ, Thong\u00a0M, Wang\u00a0Y (2023) The diagnostic and prognostic role of biomarkers in chronic rhinosinusitis. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics13040715","journal-title":"Diagnostics"},{"key":"1635_CR184","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaci.2016.06.063","volume":"139","author":"BK Tan","year":"2017","unstructured":"Tan\u00a0BK et\u00a0al (2017) Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J\u00a0Allergy Clin Immunol 139:699\u2013703.e7. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.063","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR185","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","volume":"7","author":"WW Stevens","year":"2019","unstructured":"Stevens\u00a0WW et\u00a0al (2019) Associations between inflammatory Endotypes and clinical presentations in chronic rhinosinusitis. J\u00a0Allergy Clin Immunol Pract 7:2812\u20132820.e13. https:\/\/doi.org\/10.1016\/j.jaip.2019.05.009","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1635_CR186","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","volume":"145","author":"C Bachert","year":"2020","unstructured":"Bachert\u00a0C et\u00a0al (2020) Biologics for chronic rhinosinusitis with nasal polyps. J\u00a0Allergy Clin Immunol 145:725\u2013739. https:\/\/doi.org\/10.1016\/j.jaci.2020.01.020","journal-title":"J Allergy Clin Immunol"},{"key":"1635_CR187","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/all.15982","volume":"79","author":"PW Hellings","year":"2024","unstructured":"Hellings\u00a0PW et\u00a0al (2024) EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. Allergy 79:1123\u20131133. https:\/\/doi.org\/10.1111\/all.15982","journal-title":"Allergy"},{"key":"1635_CR188","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4193\/Rhin22.344","volume":"61","author":"PW Hellings","year":"2023","unstructured":"Hellings\u00a0PW et\u00a0al (2023) The EUFOREA pocket guide for chronic rhinosinusitis. Rhinology 61:85\u201389. https:\/\/doi.org\/10.4193\/Rhin22.344","journal-title":"Rhinology"},{"key":"1635_CR189","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4193\/Rhin21.477","volume":"60","author":"C Hopkins","year":"2022","unstructured":"Hopkins\u00a0C (2022) Ethical dilemmas associated with the introduction of biologic treatments in chronic rhinosinusitis with nasal polyps. Rhinology 60:162\u2013168. https:\/\/doi.org\/10.4193\/Rhin21.477","journal-title":"Rhinology"},{"key":"1635_CR190","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00106-024-01487-y","volume":"72","author":"HM Appel","year":"2024","unstructured":"Appel\u00a0HM, Lochbaum\u00a0R, Hoffmann\u00a0TK, Hahn\u00a0J (2024) Chronic rhinosinusitis with nasal polyps-extension of dupilumab treatment intervals. HNO 72:499\u2013503. https:\/\/doi.org\/10.1007\/s00106-024-01487-y","journal-title":"HNO"},{"key":"1635_CR191","doi-asserted-by":"publisher","first-page":"317","DOI":"10.21053\/ceo.2024.00233","volume":"17","author":"SY Yoon","year":"2024","unstructured":"Yoon\u00a0SY, Cha\u00a0H, Hong\u00a0SN, Yang\u00a0MS, Kim\u00a0DW (2024) Therapeutic effectiveness of SNOT 22-based Interdose interval adjustment of dupilumab for chronic rhinosinusitis with nasal polyps. Clin Exp Otorhinolaryngol 17:317\u2013325. https:\/\/doi.org\/10.21053\/ceo.2024.00233","journal-title":"Clin Exp Otorhinolaryngol"},{"key":"1635_CR192","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/alr.23168","volume":"13","author":"AR Sedaghat","year":"2023","unstructured":"Sedaghat\u00a0AR et\u00a0al (2023) Determinants of physician assessment of chronic rhinosinusitis disease control using EPOS 2020 criteria and the importance of incorporating patient perspectives of disease control. Int Forum Allergy Rhinol 13:2004\u20132017. https:\/\/doi.org\/10.1002\/alr.23168","journal-title":"Int Forum Allergy Rhinol"},{"key":"1635_CR193","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4193\/Rhin23.335","volume":"61","author":"AR Sedaghat","year":"2023","unstructured":"Sedaghat\u00a0AR et\u00a0al (2023) Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study. Rhinology 61:519\u2013530. https:\/\/doi.org\/10.4193\/Rhin23.335","journal-title":"Rhinology"},{"key":"1635_CR194","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11882-023-01118-6","volume":"24","author":"M Caminati","year":"2024","unstructured":"Caminati\u00a0M et\u00a0al (2024) Remission in type\u00a02 inflammatory diseases: current evidence, unmet needs, and suggestions for defining remission in chronic rhinosinusitis with nasal polyps. Curr Allergy Asthma Rep 24:11\u201323. https:\/\/doi.org\/10.1007\/s11882-023-01118-6","journal-title":"Curr Allergy Asthma Rep"},{"key":"1635_CR195","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0183-2021","author":"WW Busse","year":"2022","unstructured":"Busse\u00a0WW, Melen\u00a0E, Menzies-Gow\u00a0AN (2022) Holy Grail: the journey towards disease modification in asthma. Eur Respir Rev. https:\/\/doi.org\/10.1183\/16000617.0183-2021","journal-title":"Eur Respir Rev"},{"key":"1635_CR196","doi-asserted-by":"publisher","first-page":"103050","DOI":"10.1016\/j.eclinm.2024.103050","volume":"80","author":"M Lommatzsch","year":"2025","unstructured":"Lommatzsch\u00a0M et\u00a0al (2025) Roads to remission: evolving treatment concepts in type\u00a02 inflammatory diseases. EClinicalMedicine 80:103050. https:\/\/doi.org\/10.1016\/j.eclinm.2024.103050","journal-title":"EClinicalMedicine"},{"key":"1635_CR197","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s15007-024-6310-5","volume":"33","author":"M Jutel","year":"2024","unstructured":"Jutel\u00a0M et\u00a0al (2024) Neue Nomenklatur allergischer Erkrankungen nach EAACI-Standard. Allergo\u00a0J 33:16\u201324. https:\/\/doi.org\/10.1007\/s15007-024-6310-5","journal-title":"Allergo J"},{"key":"1635_CR198","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s15007-023-5742-7","volume":"32","author":"L Klimek","year":"2023","unstructured":"Klimek\u00a0L et\u00a0al (2023) Endoskopisches Scoring von Nasenpolypen: Executive Summary des EAACI-Positionspapiers: European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis. Allergo\u00a0J 32:18\u201325. https:\/\/doi.org\/10.1007\/s15007-023-5742-7","journal-title":"Allergo J"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-025-01635-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-025-01635-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-025-01635-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T10:19:15Z","timestamp":1750673955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-025-01635-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":198,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s00106-025-01635-y","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"type":"print","value":"0017-6192"},{"type":"electronic","value":"1433-0458"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"1 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Becker hat Zuwendungen f\u00fcr Beratung, Forschung und Vortr\u00e4ge erhalten von ALK-Abell\u00f3, Allergopharma, Allergy Therapeutics, Ambu, AstraZeneca, Altamira AG, Auris medical, Bencard Allergie, GSK, HAL Allergie, MSD, Mylan, Novartis, Sanofi-Genzyme, Stryker und Viatris. Sven Becker ist Vize-Pr\u00e4sident des \u00c4rzteverbandes Deutscher Allergologen AeDA, Vorsitzender der Arbeitsgemeinschaft Klinische Immunologie, Allergologie und Umweltmedizin der Deutschen Gesellschaft f\u00fcr Hals\u2011, Nasen- und Ohren-Heilkunde, Kopf- und Hals-Chirurgie sowie Stellv. Vorsitzender des Deutschen CRS-Registers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}